Biocompatibles reworks Abbott/Endeavor deal
This article was originally published in Clinica
Executive Summary
UK drug delivery specialist Biocompatibles International saw its stock rise 8% last Friday (May 25) after announcing it had renegotiated a potentially lucrative deal with existing licensing partner Abbott to supply polymer for Medtronic's Endeavor drug-eluting stent (DES).